Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders Nakajima K; Yoshita M; Matsuo S; Taki J; Kinuya SQ J Nucl Med Mol Imaging 2008[Dec]; 52 (4): 378-87Iodine-123-labeled metaiodobenzylguanidine (MIBG) has a history of over 20 years as a marker of myocardial sympathetic activity in Japan and has been used for various cardiac diseases. Aside from conventional utilities in patients with cardiac diseases, including ischemic heart diseases, cardiomyopathy, heart failure and diabetes, neurological disorders have recently been drawing special attention. The [(123)I]MIBG study showed markedly decreased myocardial uptake in Parkinson's disease, dementia with Lewy bodies and pure autonomic failure, which is a common feature of Lewy-body diseases. The MIBG study can be used for differentiating patients with extrapyramidal signs and dementia. The unique application of MIBG in movement disorders and related neurological diseases is one of its most common uses in Japan, and further studies are expected worldwide.|*3-Iodobenzylguanidine/metabolism[MESH]|Alzheimer Disease/complications/diagnosis/metabolism/physiopathology[MESH]|Diagnosis, Differential[MESH]|Humans[MESH]|Lewy Body Disease/*complications/*diagnostic imaging/metabolism[MESH]|Parkinson Disease/diagnosis/metabolism/pathology/physiopathology[MESH]|Radionuclide Imaging[MESH]|Sympathetic Nervous System/*diagnostic imaging/metabolism[MESH] |